ProCE Banner Activity

Contemporary HIV Treatment and Prevention 2022: Integrating New Data From CROI 2022

Slideset Download

Read expert faculty members’ summaries of key HIV studies from CROI 2022, including results from studies of prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Released: May 02, 2022

Expiration: May 01, 2023

Share

Faculty

Joseph J. Eron, Jr.

Joseph J. Eron, Jr., MD

Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology, Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Daniel R Kuritzkes

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeffrey Kwong

Jeffrey Kwong, DNP, MPH, AGPCNP-BC, FAANP, FAAN, AAHIVS, ACRN

Professor, Division of Advanced Nursing Practice
Rutgers, The State University of New Jersey
Newark, New Jersey
Nurse Practitioner
Gotham Medical Group
New York, New York

Milena Murray

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Provided by

Jointly provided by the Association of Nurses in AIDS Care and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology, Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV; researcher: Gilead Sciences, ViiV.

Jeffrey Kwong, DNP, MPH, AGPCNP-BC, FAANP, FAAN, AAHIVS, ACRN

Professor, Division of Advanced Nursing Practice
Rutgers, The State University of New Jersey
Newark, New Jersey
Nurse Practitioner
Gotham Medical Group
New York, New York

Jeffrey Kwong, DNP, MPH, FAANP, FAAN, has no relevant conflicts of interest to report.

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, has disclosed that she has received consultant/advisor/speaker fees from Gilead, Janssen, Merck, Theratechnologies and ViiV Healthcare.

Faculty Disclosure

Primary Author

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare and consultant/advisor/speaker fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare, and ViroStatics.